SLC2A9 and hyperuricemia: Berberrubine has also been shown to reduce hepatic XOD activity, downregulate the expression of Glut9 and Urat1 and upregulate the expression of Oat1/3 and Abcg2 at both the protein and mRNA levels in mice with hyperuricemia as well as to suppress activation of the JAK/STAT3 signaling pathway (Lin et al., 2021).